{"id":"W2975383698","doi":"10.1136/annrheumdis-2019-215386","title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial","year":2019,"lang":"en","type":"article","venue":"Annals of the Rheumatic Diseases","topic":"Spondyloarthritis Studies and Treatments","field":"Medicine","cited_by":288,"is_retracted":false,"has_abstract":true,"ca_institutions":"SKiN Health","funders":"Pfizer; Eli Lilly and Company; Amgen","keywords":"Medicine; Ixekizumab; Adalimumab; Psoriatic arthritis; Internal medicine; Adverse effect; Rheumatology; Psoriasis; Quality of life (healthcare); Physical therapy; Secukinumab; Disease; Dermatology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002594316,0.000225421,0.00150158,0.00006948014,0.00006664727,0.00001111888,0.000238932,0.00006086462,0.00001249749],"category_scores_gemma":[0.001596683,0.0001154451,0.0001104154,0.0003285425,0.0003067881,0.00008269026,0.00029401,0.000094861,7.451706e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001671183,"about_ca_system_score_gemma":0.0001089455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003466561,"about_ca_topic_score_gemma":0.000154145,"domain_scores_codex":[0.9976859,0.0002909219,0.001083151,0.0002931458,0.0004262574,0.0002206416],"domain_scores_gemma":[0.9971322,0.001080545,0.000933981,0.0005058963,0.0002448455,0.0001025681],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.7273342,0.01309113,0.09097876,0.0005192586,0.001186117,0.000001732616,0.002459201,0.00003097919,0.0000235694,0.00005356585,0.0001288112,0.1641927],"study_design_scores_gemma":[0.414265,0.006885418,0.5721676,0.005080637,0.0002328034,0.00000112512,0.0007321895,0.00003835054,0.0003500904,0.0001378504,0.00001045181,0.00009844919],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9910476,0.002524303,9.177949e-7,0.0004598158,0.0001097856,0.005178005,0.000584725,0.000004725169,0.00009011281],"genre_scores_gemma":[0.9989336,0.0008013198,0.0000789078,0.00004863036,0.000006183417,0.00008481646,0.00001930187,0.00001335689,0.00001392981],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4811889,"threshold_uncertainty_score":0.4707716,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08465387686902026,"score_gpt":0.365823190280827,"score_spread":0.2811693134118067,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}